Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.
1. A compound comprising: a tumor-binding domain, an albumin-binding domain, and a radionuclide, wherein the tumor-binding domain comprises an active site that is distal to and sterically unimpeded by the albumin-binding domain and the radionuclide, and the relative affinity of the tumor-binding domain and the albumin-binding domain differ in specific affinity by a factor of at least 100 to about 10,000; wherein the tumor-binding domain binds to a tumor associated molecular target selected from one or more of a tumor-specific cell surface protein, somatostatin peptide receptor-2 (SSTR2), alphavbeta3 (αvβ3), alphavbeta6, a gastrin-releasing peptide receptor, a seprase, fibroblast activation protein alpha (FAP-alpha), an incretin receptor, a glucose-dependent insulinotropic polypeptide receptor, VIP-1, NPY, LHRH, a neuronal transporter, a noradrenaline transporter (NET), EGFR, HER-2, VGFR, MUC-1, CEA, MUC-4, ED2, TF-antigen, an endothelial specific marker, neuropeptide Y, uPAR, TAG-72, a claudin, a CCK analog, VIP, bombesin, VEGFR, a tumor-specific cell surface protein, GLP-1, CXCR4, Hepsin, TMPRSS2, a caspace, cMET, or an overexpressed peptide receptor.
2. The compound of claim 1 , wherein the tumor-binding domain binds to the tumor associated molecular target with moderate to high affinity.
3. The compound of claim 1 , wherein the radionuclide is an auger electron-emitting radionuclide, a beta-emitting radionuclide, or an alpha-emitting radionuclide.
4. A compound comprising:
a multi-targeted agent having a plurality of sterically unimpeded targeting domains, comprising a first targeting domain comprising a blood-protein binding domain having specific affinity for binding human serum albumin in the range of about 0.25 to 50 micromolar, and a second targeting domain comprising a tumor-binding domain having specific affinity for a tumor associated molecular target in the range of about 0.1 to 75 nanomolar; wherein the relative affinities of the first and second targeting domains differ in specific affinity by a factor of at least 100 to about 10,000, and wherein the tumor associated molecular target is selected from one or more of a tumor-specific cell surface protein, somatostatin peptide receptor-2 (SSTR2), alphavbeta3 (αvβ3), alphavbeta6, a gastrin-releasing peptide receptor, a seprase, fibroblast activation protein alpha (FAP-alpha), an incretin receptor, a glucose-dependent insulinotropic polypeptide receptor, VIP-1, NPY, LHRH, a neuronal transporter, a noradrenaline transporter (NET), EGFR, HER-2, VGFR, MUC-1, CEA, MUC-4, ED2, TF-antigen, an endothelial specific marker, neuropeptide Y, uPAR, TAG-72, a claudin, a CCK analog, VIP, bombesin, VEGFR, a tumor-specific cell surface protein, GLP-1, CXCR4, Hepsin, TMPRSS2, a caspace, cMET, or an overexpressed peptide receptor; and
a therapeutic domain comprising a radionuclide.
5. The compound of claim 4 , wherein the tumor-binding domain binds to the tumor associated molecular target with moderate to high affinity.
6. The compound of claim 4 , wherein the radionuclide is an auger electron-emitting radionuclide, a beta-emitting radionuclide, or an alpha-emitting radionuclide.
7. The compound of claim 4 , wherein the therapeutic domain comprises a covalently conjugated chelating agent or a covalently conjugated polyaza polycarboxylic macrocycle.
8. The compound of claim 7 , wherein the radionuclide is an auger electron-emitting radionuclide, a beta-emitting radionuclide, or an alpha-emitting radionuclide.
9. A compound comprising:
a multi-targeted agent having a plurality of sterically unimpeded targeting domains comprising, a first targeting domain comprising a blood-protein binding domain having specific affinity for binding human serum albumin in the range of about 0.25 to 50 micromolar, a second targeting domain comprising a tumor-binding domain having specific affinity for fibroblast activation protein alpha (FAP-alpha) in the range of about 0.1 to 75 nanomolar;
wherein the relative affinities of the first and second targeting domains differ in specific affinity by a factor of at least 100 to about 10,000; and
a therapeutic domain comprising a radionuclide.
10. The compound of claim 9 , wherein the blood-protein binding domain binds human serum albumin with an affinity in the range of about 0.4 to 20 micromolar, and the tumor-binding domain binds FAP-alpha with an affinity in the range of about 0.1 to 15 nanomolar; wherein the relative affinities of the first and second targeting domains differ in specific affinity by a factor of about 1,000 to about 10,000.
11. The compound of claim 9 , wherein the blood-protein binding domain is selected from one or more of myristic acid, a substituted or unsubstituted indole-2-carboxylic acid, a substituted or unsubstituted thioamide, a substituted or unsubstituted 4-oxo-4-(5,6,7,8-tetrahydronaphthalen-2-yl)butanoic acid, a substituted or unsubstituted naphthalene acylsulfonamide, a substituted or unsubstituted diphenylcyclohexanol phosphate ester, a substituted or unsubstituted 4-iodophenylalkanoic acid, a substituted or unsubstituted 3-(4-iodophenyl)propionic acid, a substituted or unsubstituted 2-(4-iodophenyl)acetic acid, or a substituted or unsubstituted 4-(4-iodophenyl)butanoic acid.
12. The compound of claim 9 , wherein the tumor-binding domain binds to the FAP-alpha with moderate to high affinity.
13. The compound of claim 9 , wherein the radionuclide is an auger electron-emitting radionuclide, a beta-emitting radionuclide, or an alpha-emitting radionuclide.
14. The compound of claim 9 , wherein the therapeutic domain comprises a covalently conjugated chelating agent or a covalently conjugated polyaza polycarboxylic macrocycle.
15. The compound of claim 14 , wherein the radionuclide is an auger electron-emitting radionuclide, a beta-emitting radionuclide, or an alpha-emitting radionuclide.